Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FaR-RMS: Rhabdomyosarcoma Study
NCT04625907Phase 2Recruiting
- Sponsor
- University of Birmingham
- Start
- Sep 2020
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 2 trial of irinotecan, regorafenib, vinorelbine in rhabdomyosarcoma (RMS), sponsored by University of Birmingham. Started Sep 2020; status: recruiting.
02
Drugs
irinotecanregorafenibvinorelbine
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT04625907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625907.